Thymosin Alpha-1: A Research Overview

Introduction

Thymosin Alpha-1 (Tα1), also known by its pharmaceutical name thymalfasin and the trade name Zadaxin, is a 28-amino-acid peptide originally isolated from calf thymus tissue. It holds one of the most extensive research records of any peptide in its class, spanning more than four decades of clinical and preclinical investigation across virology, oncology, and critical-care research contexts. Thymalfasin has received regulatory approval in more than 30 countries — including approvals in Asia-Pacific, Latin America, and Eastern Europe — making it among the most internationally recognized thymic peptides in clinical translation. In the United States, thymalfasin holds multiple FDA orphan-drug designations and has been under active regulatory review for compounding frameworks. This article is an educational reference summarizing the compound's chemical identity, pharmacological classification, and regulatory status based on peer-reviewed publications and regulatory documents. The receptor-level pharmacology underlying these research contexts is covered in detail in the Thymosin Alpha-1 mechanism of action article.

Background

Research interest in thymosin-family peptides originated in the early 1960s in work initiated at the Albert Einstein College of Medicine under Abraham White and extended by Allan L. Goldstein, who subsequently moved the program to the University of Texas Medical Branch at Galveston and then to George Washington University. The broader thymosin research program proceeded in two productive phases: first the isolation and characterization of "thymosin fraction 5," a partially purified calf-thymus preparation containing multiple heat-stable acidic peptides; second, the resolution of that fraction into discrete molecular species, among which Tα1 emerged as the most extensively characterized [1].

A 2007 narrative review by Goldstein and Goldstein, published in Annals of the New York Academy of Sciences, traced the full lineage from the 1966 naming of thymosin through the eventual clinical development of Tα1 under the SciClone Pharmaceuticals banner, summarizing the transition from preclinical characterization to human clinical trials [2].

A 2020 comprehensive review by Dominari and colleagues, published in the World Journal of Virology, surveyed the breadth of published clinical applications and confirmed that Tα1 remains the most thoroughly investigated peptide derived from the thymosin fraction 5 isolation program [3].

Chemistry and Structure

Thymosin Alpha-1 is a 28-amino-acid peptide with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn, where "Ac" denotes an N-terminal acetyl group. Its molecular weight is approximately 3,108 daltons and its isoelectric point is approximately pH 4.2, making it a highly acidic molecule.

The seminal 1977 publication by Goldstein and colleagues in the Proceedings of the National Academy of Sciences USA first reported the complete primary sequence and confirmed that Tα1 was heat-stable and highly acidic — properties that distinguished it from many other biologically active peptides and that facilitated its purification from thymosin fraction 5 [4].

A 2012 nuclear magnetic resonance (NMR) structure of human Tα1 was reported by Nepravishta and colleagues in FEBS Journal, characterizing the peptide's secondary structure in a membrane-mimicking environment. The authors reported two stable structural regions: an alpha-helix spanning approximately residues 14 to 26, and a distorted helical arrangement formed by two double β-turns in the N-terminal twelve residues [5]. This structural characterization was noted as potentially relevant to the peptide's reported interactions with membrane-associated receptor complexes.

The synthetic form of Tα1 used in research and in approved pharmaceutical preparations, termed thymalfasin, is chemically identical in amino acid sequence and N-terminal acetylation to the naturally occurring peptide isolated from thymic tissue. It is produced via solid-phase peptide synthesis.

Pharmacological Classification

In the peer-reviewed literature, Tα1 is classified as a thymic immunomodulatory peptide with a well-characterized TLR-pathway pharmacology. The molecular precision of this classification has deepened considerably since 2006, when landmark studies by Romani and colleagues established the TLR9/dendritic-cell framework that now represents the dominant mechanistic paradigm in the field. Comparable thymic and tissue-derived peptides investigated in overlapping research contexts include TB-500, whose published literature spans wound-healing and anti-inflammatory animal models using a distinct actin-sequestration mechanism.

Published mechanistic studies have characterized Tα1 as a Toll-like receptor (TLR) pathway modulator with preferential activity at plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells (mDCs). Key publications by Romani and colleagues, including a 2006 study in Blood and a 2007 study in International Immunology, identified TLR9-dependent and TLR2-dependent signaling as the primary molecular pharmacology underlying the peptide's reported effects on interferon production and tryptophan catabolism [6,7]. This TLR-pathway framing has become the dominant mechanistic paradigm in post-2006 Tα1 pharmacology literature, providing a molecularly specific basis for the compound's extensive research history.

Earlier descriptions of Tα1 as a broadly acting "immune modulator" appear frequently in clinical trial publications from the 1990s and early 2000s; this language reflects the vocabulary of the period rather than a mechanistically precise classification. Contemporary reviews distinguish this earlier terminology from the more specific TLR9/dendritic-cell framework.

Regulatory Status

Thymalfasin (Zadaxin) is approved in more than 30 countries for indications that vary by jurisdiction but have centered on hepatitis B and, in some markets, hepatitis C and hepatocellular carcinoma. This international regulatory footprint — concentrated in Asia, Latin America, and Eastern Europe — reflects clinical trial programs conducted primarily during the 1990s through the 2010s and positions Tα1 as among the most broadly approved thymic peptides worldwide [3].

In the United States, the FDA has granted orphan-drug designation to thymalfasin for several conditions, including chronic active hepatitis B, malignant melanoma, DiGeorge anomaly with immune defects, and hepatocellular carcinoma, as documented in regulatory records and summarized in published reviews [3]. Orphan-drug designation under the Orphan Drug Act of 1983 confers specific development incentives and does not constitute marketing authorization. In 2024, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed bulk drug substances nominated for inclusion on the 503B compounding list, a process that placed Tα1 under formal regulatory scrutiny in the US context [8].

Discovery History

The discovery of Tα1 followed a sequential process of thymic extract fractionation spanning more than a decade. The foundational naming of thymosin as a class of thymic polypeptides occurred in 1966 in a publication by Goldstein, Slater, and White in the Proceedings of the National Academy of Sciences USA [2]. Subsequent work at the University of Texas Medical Branch at Galveston and at George Washington University by Goldstein and colleagues resolved thymosin fraction 5 into its individual molecular components.

The 1977 PNAS paper by Goldstein and colleagues (PMID 265536) reported the complete amino acid sequence of Tα1 for the first time, establishing it as a distinct 28-residue peptide within the broader thymosin fraction 5 mixture [4]. A complementary 1979 paper by Low, Thurman, Chincarini, McClure, Marshall, Xu, and Goldstein in the Journal of Biological Chemistry (PMID 216684) provided detailed isolation, characterization, and biological activity data for both thymosin alpha1 and polypeptide beta1 from calf thymus [9].

SciClone Pharmaceuticals subsequently licensed and advanced thymalfasin (Zadaxin) through clinical development. The compound received its first regulatory approvals in Asia during the 1990s, and SciClone's development program was reviewed in a 2002 clinical pharmacology publication in Expert Opinion on Investigational Drugs [10]. Research-grade Thymosin Alpha-1 from SpartaLabs is verified by independent third-party analysis.

References

1. Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA. 1966;56(3):1010–1017. PMID: 5230555. https://pubmed.ncbi.nlm.nih.gov/5230555/

2. Goldstein AL, Goldstein AL. History of the discovery of the thymosins. Ann N Y Acad Sci. 2007;1112:1–13. PMID: 17600284. DOI: 10.1196/annals.1415.001. https://pubmed.ncbi.nlm.nih.gov/17600284/

3. Dominari A, Hathaway D 3rd, Pandav K, Vasan S, Dhindsa DS, Dave K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67–78. PMID: 33362999. PMC7747025. DOI: 10.5501/wjv.v9.i5.67. https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/

4. Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio J, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977;74(2):725–729. PMID: 265536. PMC392366. https://pmc.ncbi.nlm.nih.gov/articles/PMC392366/

5. Nepravishta R, Mandaliti W, Valente S, Alagna NS, Labruna S, Pica F, et al. NMR structure of human thymosin alpha-1. FEBS J. 2012;279(3):401–409. PMID: 22115779. DOI: 10.1111/j.1742-4658.2011.08428.x. https://pubmed.ncbi.nlm.nih.gov/22115779/

6. Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, et al. Thymosin alpha 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265–2274. PMID: 16741252. DOI: 10.1182/blood-2006-02-004762. https://pubmed.ncbi.nlm.nih.gov/16741252/

7. Romani L, Bistoni F, Montagnoli C, Gaziano R, Bozza S, Fallarino F, et al. Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. Int Immunol. 2007;19(10):1261–1271. PMID: 17804687. DOI: 10.1093/intimm/dxm099. https://pubmed.ncbi.nlm.nih.gov/17804687/

8. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) Meeting — Thymosin Alpha-1 (Tα1) Related Bulk Drug Substances. FDA Briefing Document. 2024. https://www.fda.gov/media/183892/download

9. Low TL, Thurman GB, Chincarini C, McClure JE, Marshall GD, Xu SH, Goldstein AL. The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus. J Biol Chem. 1979;254(3):981–986. PMID: 216684. https://pubmed.ncbi.nlm.nih.gov/216684/

10. Tuthill C, Rios I, McBeath R. Thymosin alpha1. SciClone Pharmaceuticals. Curr Opin Investig Drugs. 2002;3(7):1085–1090. PMID: 12090542. https://pubmed.ncbi.nlm.nih.gov/12090542/